Comment: FTC challenges Illumina-PacBio merger on monopoly claims; case could be precursor for Big Tech battles
The US Federal Trade Commission voted 5-0 to challenge Illumina’s proposed acquisition of Pacific Biosciences, claiming Illumina is trying to maintain its monopoly in the US market for DNA sequencing systems....To view the full article, register now.
Already a subscriber? Click here to view full article